| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1b/2a interim results example | BB-301 Dysphagia associated with Oculopharyngeal Muscular Dystrophy (OPMD) | Phase 1b/2a | — | - | - | ||
Phase 1b/2a interim results example | BB-301 Dysphagia associated with Oculopharyngeal Muscular Dystrophy (OPMD) | Phase 1b/2a | — | - | - | ||
Phase 1b/2a interim results example | BB-301 Dysphagia associated with Oculopharyngeal Muscular Dystrophy (OPMD) | Phase 1b/2a | — | - | - |
Recent Updates
Recently added Catalysts
Benitec Biopharma Inc.$11.83
+0.73 (+6.58%)
D 33Pipeline Score Overvalued Biotech · Clinical
Market Cap
385.80 M
EPS
-0.93
P/E Ratio
-
Value Trade
924.11 K
SEC Financials
Q1 2026Dilution Risk
Revenue
-
R&D Expenses
6.30 M
Total Assets
187.00 M
Total Liabilities
3.67 M
Equity
183.33 M
D/E Ratio
12,345
-1.23 %
Week
-15.5 %
1 Month
4.56 %
3 Month
-14.08 %
6 Month
-84.99 %
5 Year
-99.53 %
All Time
Cash Data
Cash Position
184.76 M
Monthly Burn
4.53 M
Runway
39.9 mo
Burn Trend
StableSEC Filing
May 14, 2026
Overview
Volume
30.60 K
52 Week Range
9.85 - 17.15
% held by Insiders
2.7 %
% held by Institutions
98.11 %
Enterprise Value
201.80 M
Total Shares
34.35 M
Short %
6.98 %
Float Shares
21.09 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D33
Pipeline Score $82M
Pipeline ValueOvervalued
Valuation Signal1
Drugs Scored0.2x
rNPV / MCap Top 44%
Micro Cap (rank 508 of 905)
Percentile RankBenitec Biopharma Inc. faces pipeline headwinds (33/100), with $205M risk-adjusted pipeline value, led by BB-401 in Head and Neck Squamous Cell Carcinoma (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BB-401 Small molecule | Head and Neck Squamous Cell Carcinoma | Phase 2 | NCT03433027 | 10% | $205M | COMPLETED | 16 | - | - | Apr 6, 2020 | - | Apr 15, 2020 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
BB-301 | Oculopharyngeal Muscular Dystrophy (OPMD) | Phase 1b/2a | 2025-07-10 | |||
BB-301 | Oculopharyngeal Muscular Dystrophy (OPMD) | Phase 1b/2a | 2025-07-10 | |||
BB-301 | Oculopharyngeal Muscular Dystrophy (OPMD) | Phase 1b/2a | 2025-07-10 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BNTC
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Benitec Biopharma Inc. (BNTC) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
BNTC
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BNTC
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BNTC
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BNTC Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
BNTC Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
BNTCBenitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting
Benitec Biopharma announced the acceptance of interim results from its BB-301 Phase 1b/2a study for Oculopharyngeal Muscular Dystrophy (OPMD). The results, which show durable improvements in patients, will be presented at the 2026 ASGCT Annual Meeting. BB-301 is a unique gene therapy targeting dysphagia in OPMD patients, with no approved therapies currently available.
Read more →BNTCBenitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
Benitec Biopharma announced positive interim results from its Phase 1b/2a study of BB-301 for Oculopharyngeal Muscular Dystrophy (OPMD). Patients receiving both low and high doses of BB-301 showed significant improvements in swallowing function, with durable effects lasting up to two years. The high dose demonstrated a robust response, indicating potential for disease-modifying outcomes.
Read more →BNTCBenitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference
Benitec Biopharma has announced the acceptance of a late-breaking abstract for its BB-301 Phase 1b/2a clinical study at the Muscular Dystrophy Association Clinical & Scientific Conference. The study focuses on treating Oculopharyngeal Muscular Dystrophy (OPMD) patients with moderate dysphagia. Interim results for both Cohort 1 and Cohort 2 will be presented, highlighting the potential of BB-301 as a treatment option.
Read more →BNTCBenitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update
Benitec Biopharma reported positive results from its BB-301 Phase 1b/2a study, with all four patients in Cohort 1 showing durable responses after 12 months. Patient 1 continued to experience significant improvements at the 24-month follow-up. The company plans to engage with the FDA regarding the pivotal study design in mid-2026 and has received Fast Track Designation for BB-301.
Read more →BNTCBenitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offering
Benitec Biopharma Inc. has announced the pricing of a $100 million common stock offering, which includes an underwritten public offering of 5,930,000 shares and a direct offering of 1,481,481 shares. The proceeds will be used to support product candidate programs and general corporate purposes. The offerings are set to close on November 7, 2025.
Read more →BNTCBenitec Biopharma Inc. Announces Proposed Public Offering
Benitec Biopharma Inc. has announced a proposed public offering of its common stock, alongside a registered direct offering with Suvretta Capital. The offerings are set to close on November 7, 2025, pending customary conditions. The company aims to raise funds to support its gene therapy initiatives, although market conditions may affect the final terms.
Read more →BNTCBenitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301
Benitec Biopharma announced positive interim results from its BB-301 Phase 1b/2a clinical trial, showing a 100% response rate among patients with Oculopharyngeal Muscular Dystrophy (OPMD). The FDA has granted Fast Track designation for BB-301, highlighting the urgent need for effective treatments for dysphagia associated with OPMD. The trial results indicate significant improvements in multiple clinical measures.
Read more →BNTCBenitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of Directors
Benitec Biopharma has appointed Dr. Sharon Mates to its Board of Directors, effective November 2, 2025. Dr. Mates, who has a strong background in biotechnology, is expected to contribute significantly to the company's BB-301 program aimed at treating Oculopharyngeal Muscular Dystrophy (OPMD). Her experience in advancing therapies from discovery to commercialization will be valuable as Benitec seeks regulatory approval for its innovative treatments.
Read more →BNTCBenitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy
Benitec Biopharma announced an upcoming update on its Phase 1b/2a clinical study of BB-301 for Oculopharyngeal Muscular Dystrophy (OPMD). The update will cover six patients from the initial cohort. The webcast is scheduled for November 3, 2025, at 8:00 am EST, reflecting the company's commitment to transparency in its clinical trials.
Read more →BNTCBenitec Biopharma Releases Full Year 2025 Financial Results and Provides Operational Update
Benitec Biopharma reported its financial results for the year ending June 30, 2025, highlighting an increase in operational losses and expenses. The company anticipates interim results for Cohort 1 of its BB-301 Phase 1b/2a study in Q4 2025 and has received approval to begin enrollment for Cohort 2. The financial report indicates a substantial cash reserve of $97.7 million.
Read more →BNTCBenitec Biopharma Provides Operational Updates
Benitec Biopharma announced that the independent Data Safety Monitoring Board has recommended the continuation of subject enrollment for its Phase 1b/2a clinical study of BB-301. The sixth and final subject of Cohort 1 was treated safely, and enrollment for Cohort 2 is expected to begin in Q4 2025. The company is optimistic about the safety profile of BB-301, which utilizes a local delivery method.
Read more →BNTCBenitec Biopharma Reports Positive Interim Clinical Results for Three Subjects Treated with BB-301 in Phase 1b/2a Study to be Presented at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
Benitec Biopharma reported positive interim results from its Phase 1b/2a study of BB-301 in treating Oculopharyngeal Muscular Dystrophy (OPMD). Three subjects showed significant improvements in swallowing function, with two achieving clinically normal profiles. These results will be presented at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference.
Read more →Competitive Position
How BNTC ranks across every disease it competes inCompetitive Position is a premium feature
See how BNTC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial